Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Oramed Pharmaceuticals (ORMP) Invested Capital (2016 - 2026)

Oramed Pharmaceuticals filings provide 15 years of Invested Capital readings, the most recent being $199.7 million for Q4 2025.

  • Quarterly Invested Capital rose 36.56% to $199.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $199.7 million through Dec 2025, up 36.56% year-over-year, with the annual reading at $199.7 million for FY2025, 36.56% up from the prior year.
  • Invested Capital hit $199.7 million in Q4 2025 for Oramed Pharmaceuticals, down from $203.3 million in the prior quarter.
  • Across five years, Invested Capital topped out at $223.6 million in Q3 2023 and bottomed at $49.5 million in Q1 2021.
  • Average Invested Capital over 5 years is $156.7 million, with a median of $153.4 million recorded in 2022.
  • The largest annual shift saw Invested Capital soared 501.15% in 2021 before it tumbled 31.62% in 2024.
  • Oramed Pharmaceuticals' Invested Capital stood at $170.2 million in 2021, then fell by 11.17% to $151.2 million in 2022, then soared by 41.51% to $213.9 million in 2023, then tumbled by 31.62% to $146.3 million in 2024, then soared by 36.56% to $199.7 million in 2025.
  • Per Business Quant, the three most recent readings for ORMP's Invested Capital are $199.7 million (Q4 2025), $203.3 million (Q3 2025), and $153.6 million (Q2 2025).